Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review

Key Points

• Advances in SGLT2 inhibitors and GLP-1 receptor agonists improve outcomes for type 2 diabetes patients.
• Review covers a decade of developments in cardiovascular disease related to these therapies.
• This comprehensive review summarizes the progress made over ten years in managing type 2 diabetes.
• Findings indicate significant improvements in treatment options for cardiovascular disease patients with type 2 diabetes.

Abstract